Saltar al contenido
Merck
Todas las fotos(1)

Key Documents

Otros documentos

Y0001666

Progesterone

European Pharmacopoeia (EP) Reference Standard

Sinónimos:

Progesterone, 4-Pregnene-3,20-dione

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización
Todas las fotos(1)

About This Item

Fórmula empírica (notación de Hill):
C21H30O2
Número de CAS:
57-83-0
Peso molecular:
314.46
Beilstein:
1915950
Número MDL:
MFCD00003658
Código UNSPSC:
41116107
ID de la sustancia en PubChem:
329831529
NACRES:
NA.24

grado

pharmaceutical primary standard

familia API

progesterone

fabricante / nombre comercial

EDQM

mp

128-132 °C (lit.)

aplicaciones

pharmaceutical (small molecule)

formato

neat

cadena SMILES

CC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C

InChI

1S/C21H30O2/c1-13(22)17-6-7-18-16-5-4-14-12-15(23)8-10-20(14,2)19(16)9-11-21(17,18)3/h12,16-19H,4-11H2,1-3H3/t16-,17+,18-,19-,20-,21+/m0/s1

Clave InChI

RJKFOVLPORLFTN-LEKSSAKUSA-N

Información sobre el gen

human ... PGR(5241)

¿Está buscando productos similares? Visita Guía de comparación de productos

Descripción general

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Aplicación

Progesterone for peak identification EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Acciones bioquímicas o fisiológicas

Induces maturation and secretory activity of the uterine endothelium; suppresses ovulation. Progesterone is implicated in the etiology of breast cancer.

Envase

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Otras notas

Steroid hormone produced by the corpus luteum.
Sales restrictions may apply.

Producto relacionado

Referencia del producto
Descripción
Precios

PHR1142

Progesterone, Pharmaceutical Secondary Standard; Certified Reference Material

1568007

Progesterone, United States Pharmacopeia (USP) Reference Standard

P3300000

Progesterone, European Pharmacopoeia (EP) Reference Standard

Y0001665

Progesterone, European Pharmacopoeia (EP) Reference Standard

Y0001667

Progesterone for impurity H identification, European Pharmacopoeia (EP) Reference Standard

BP449

Progesterone, British Pharmacopoeia (BP) Reference Standard

PHR8932

(20R)-20-Hydroxypregn-4-en-3-one, Pharmaceutical Secondary Standard; Certified Reference Material

PHR8935

(20S)-20-Hydroxypregn-4-en-3-one, Pharmaceutical Secondary Standard; Certified Reference Material

PHR8943

(20S)-3-Oxopregn-4-en-20-yl acetate

Pictogramas

Health hazard
GHS08

Palabra de señalización

Danger

Frases de peligro

H351,H360FD,H362

Clasificaciones de peligro

Carc. 2 - Lact. - Repr. 1A

Código de clase de almacenamiento

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

Clase de riesgo para el agua (WGK)

WGK 3

Punto de inflamabilidad (°F)

Not applicable

Punto de inflamabilidad (°C)

Not applicable

Elija entre una de las versiones más recientes:

Certificados de análisis (COA)

Lot/Batch Number

Lo sentimos, en este momento no disponemos de COAs para este producto en línea.

Si necesita más asistencia, póngase en contacto con Atención al cliente

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Gunter von Minckwitz et al.
The Lancet. Oncology, 15(7), 747-756 (2014-05-06)
Preclinical data suggest that triple-negative breast cancers are sensitive to interstrand crosslinking agents, and that synergy may exist for the combination of a taxane, trastuzumab, and a platinum salt for HER2-positive breast cancer. We therefore aimed to assess the efficacy
Yanping Kuang et al.
Reproductive biomedicine online, 29(6), 684-691 (2014-12-03)
Previous studies have shown that existing antral follicles in the luteal phase enable ovarian stimulation. In a pilot study, the efficacy of double stimulations during the follicular and luteal phases in women with poor ovarian response was explored (defined according
Brett E Skolnick et al.
The New England journal of medicine, 371(26), 2467-2476 (2014-12-11)
Progesterone has been associated with robust positive effects in animal models of traumatic brain injury (TBI) and with clinical benefits in two phase 2 randomized, controlled trials. We investigated the efficacy and safety of progesterone in a large, prospective, phase
Eszter Papp et al.
The Journal of infectious diseases, 211(1), 10-18 (2014-07-18)
Protease inhibitor (PI)-based combination antiretroviral therapy (cART) is administered during pregnancy to prevent perinatal human immunodeficiency virus (HIV) transmission. However, PI use has been associated with adverse birth outcomes, including preterm delivery and small-for-gestational-age (SGA) births. The mechanisms underlying these
A R Harmer et al.
The Journal of physiology, 592(3), 523-535 (2013-12-04)
Calcium cycling is integral to muscle performance during the rapid muscle contraction and relaxation of high-intensity exercise. Ca(2+) handling is altered by diabetes mellitus, but has not previously been investigated in human skeletal muscle. We investigated effects of high-intensity exercise
Ver todos los artículos relacionados

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico